Symbols / ACRV $1.57 +3.29% Acrivon Therapeutics, Inc.
ACRV Chart
About
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 60.83M |
| Enterprise Value | -56.98M | Income | -77.91M | Sales | — |
| Book/sh | 3.56 | Cash/sh | 3.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 74 | IPO | — |
| P/E | — | Forward P/E | -0.84 | PEG | — |
| P/S | — | P/B | 0.44 | P/C | — |
| EV/EBITDA | 0.69 | EV/Sales | — | Quick Ratio | 7.57 |
| Current Ratio | 7.69 | Debt/Eq | 2.41 | LT Debt/Eq | — |
| EPS (ttm) | -2.02 | EPS next Y | -1.86 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 07:00 | ROA | -32.22% |
| ROE | -53.86% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 38.74M |
| Shs Float | 25.67M | Short Float | 20.00% | Short Ratio | 2.62 |
| Short Interest | — | 52W High | 3.56 | 52W Low | 1.05 |
| Beta | 1.74 | Avg Volume | 1.73M | Volume | 875.45K |
| Target Price | $11.50 | Recom | Strong_buy | Prev Close | $1.52 |
| Price | $1.57 | Change | 3.29% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2025-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-08-14 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2025-05-16 | down | Jones Trading | Buy → Hold | — |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-03-28 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2025-03-26 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-26 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $17 |
| 2025-03-26 | main | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-01-31 | init | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-14 | main | BMO Capital | Outperform → Outperform | $27 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $17 |
| 2024-09-16 | up | Ladenburg Thalmann | Neutral → Buy | $16 |
| 2024-09-16 | reit | BMO Capital | Outperform → Outperform | $28 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-05-15 | reit | BMO Capital | Outperform → Outperform | $25 |
| 2024-05-14 | main | HC Wainwright & Co. | Buy → Buy | $22 |
- ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill hu, 02 Apr 2026 07
- If You Invested $1,000 in Acrivon Therapeutics, Inc. (ACRV) - Stock Titan Sun, 22 Mar 2026 17
- FIVE,OLMA,JBL,PBF,ACRV,MU,IMRX,COSM,GLSI,SRRK | stock prices | quote comparison - Yahoo Finance UK Mon, 06 Apr 2026 10
- $ACRV stock is down 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Feb 2026 08
- Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com hu, 08 Jan 2026 08
- [SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan Mon, 23 Mar 2026 07
- Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release | ACRV Stock News - Quiver Quantitative hu, 08 Jan 2026 08
- Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - finance.yahoo.com ue, 03 Mar 2026 08
- Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan hu, 19 Mar 2026 07
- Insider Purchase: President and CEO of $ACRV Buys 49,000 Shares | ACRV Stock News - Quiver Quantitative Fri, 16 Jan 2026 08
- H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - finance.yahoo.com Fri, 28 Nov 2025 08
- New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan ue, 06 Jan 2026 08
- Cancer drug combo clears tumors in mice in Acrivon study - Stock Titan ue, 17 Mar 2026 07
- Acrivon CEO joins TD Cowen Boston health care fireside chat - Stock Titan ue, 24 Feb 2026 08
- New Analyst Forecast: $ACRV Given $19.0 Price Target - Quiver Quantitative ue, 25 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
84.11
-5.70%
|
89.20
+32.93%
|
67.10
+105.48%
|
32.66
|
| Research And Development |
|
59.99
-6.25%
|
63.99
+39.04%
|
46.02
+92.18%
|
23.95
|
| Selling General And Administration |
|
24.12
-4.30%
|
25.21
+19.58%
|
21.08
+142.06%
|
8.71
|
| General And Administrative Expense |
|
24.12
-4.30%
|
25.21
+19.58%
|
21.08
+142.06%
|
8.71
|
| Salaries And Wages |
|
—
|
18.10
+23.83%
|
14.62
+188.46%
|
5.07
|
| Other Gand A |
|
24.12
-4.30%
|
25.21
+290.20%
|
6.46
+77.47%
|
3.64
|
| Total Expenses |
|
84.11
-5.70%
|
89.20
+32.93%
|
67.10
+105.48%
|
32.66
|
| Operating Income |
|
-84.11
+5.70%
|
-89.20
-32.93%
|
-67.10
-105.48%
|
-32.66
|
| Total Operating Income As Reported |
|
-84.11
+5.70%
|
-89.20
-32.93%
|
-67.10
-105.48%
|
-32.66
|
| EBITDA |
|
-82.76
+6.16%
|
-88.19
-32.49%
|
-66.57
-106.13%
|
-32.29
|
| Normalized EBITDA |
|
-82.76
+6.16%
|
-88.19
-32.49%
|
-66.57
-106.13%
|
-32.29
|
| Reconciled Depreciation |
|
1.36
+34.79%
|
1.01
+87.69%
|
0.54
+47.25%
|
0.36
|
| EBIT |
|
-84.11
+5.70%
|
-89.20
-32.93%
|
-67.10
-105.48%
|
-32.66
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Pretax Income |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Net Non Operating Interest Income Expense |
|
6.48
-29.58%
|
9.20
+30.75%
|
7.04
|
—
|
| Net Interest Income |
|
6.48
-29.58%
|
9.20
+30.75%
|
7.04
|
—
|
| Interest Income Non Operating |
|
6.48
-29.58%
|
9.20
+30.75%
|
7.04
|
—
|
| Interest Income |
|
6.48
-29.58%
|
9.20
+30.75%
|
7.04
|
—
|
| Other Income Expense |
|
-0.27
+51.61%
|
-0.56
-73.29%
|
-0.32
-121.61%
|
1.49
|
| Other Non Operating Income Expenses |
|
-0.27
+51.61%
|
-0.56
-73.29%
|
-0.32
-121.61%
|
1.49
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Net Income From Continuing Operation Net Minority Interest |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Net Income From Continuing And Discontinued Operation |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Net Income Continuous Operations |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Normalized Income |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Net Income Common Stockholders |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Diluted EPS |
|
—
|
-2.38
+13.14%
|
-2.74
+63.76%
|
-7.56
|
| Basic EPS |
|
—
|
-2.38
+13.14%
|
-2.74
+63.76%
|
-7.56
|
| Basic Average Shares |
|
—
|
33.79
+53.06%
|
22.08
+435.63%
|
4.12
|
| Diluted Average Shares |
|
—
|
33.79
+53.06%
|
22.08
+435.63%
|
4.12
|
| Diluted NI Availto Com Stockholders |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
129.72
-34.02%
|
196.59
+42.18%
|
138.26
-23.71%
|
181.23
|
| Current Assets |
|
120.44
-33.69%
|
181.63
+40.05%
|
129.69
-1.82%
|
132.09
|
| Cash Cash Equivalents And Short Term Investments |
|
118.58
-33.93%
|
179.48
+40.82%
|
127.46
-0.23%
|
127.75
|
| Cash And Cash Equivalents |
|
41.50
+4.22%
|
39.82
+10.56%
|
36.02
+22.01%
|
29.52
|
| Other Short Term Investments |
|
77.08
-44.81%
|
139.66
+52.73%
|
91.44
-6.91%
|
98.23
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.86
-13.31%
|
2.15
-3.80%
|
2.23
-48.57%
|
4.34
|
| Total Non Current Assets |
|
9.27
-38.02%
|
14.96
+74.49%
|
8.57
-82.55%
|
49.13
|
| Net PPE |
|
7.42
-7.59%
|
8.03
+1.48%
|
7.91
+15.24%
|
6.86
|
| Gross PPE |
|
10.73
+7.48%
|
9.99
+12.67%
|
8.86
+21.72%
|
7.28
|
| Accumulated Depreciation |
|
-3.32
-69.11%
|
-1.96
-105.23%
|
-0.96
-127.62%
|
-0.42
|
| Machinery Furniture Equipment |
|
7.29
+14.37%
|
6.38
+103.87%
|
3.13
+24.48%
|
2.51
|
| Construction In Progress |
|
0.92
+1479.31%
|
0.06
-95.57%
|
1.31
|
0.00
|
| Other Properties |
|
2.53
-28.90%
|
3.55
-19.76%
|
4.43
-7.15%
|
4.77
|
| Investments And Advances |
|
0.00
-100.00%
|
5.09
|
0.00
-100.00%
|
41.88
|
| Non Current Deferred Assets |
|
1.65
+0.36%
|
1.65
+556.18%
|
0.25
|
0.00
|
| Other Non Current Assets |
|
0.20
+2.53%
|
0.20
-52.17%
|
0.41
+6.70%
|
0.39
|
| Total Liabilities Net Minority Interest |
|
17.20
-13.14%
|
19.80
+16.00%
|
17.07
+58.78%
|
10.75
|
| Current Liabilities |
|
15.66
-9.00%
|
17.21
+29.40%
|
13.30
+104.16%
|
6.52
|
| Payables And Accrued Expenses |
|
8.93
-16.51%
|
10.70
+24.92%
|
8.57
+180.03%
|
3.06
|
| Payables |
|
2.28
+200.40%
|
0.76
-84.98%
|
5.05
+458.41%
|
0.90
|
| Accounts Payable |
|
2.28
+200.40%
|
0.76
-84.98%
|
5.05
+458.41%
|
0.90
|
| Current Accrued Expenses |
|
6.66
-33.05%
|
9.94
+182.63%
|
3.52
+63.25%
|
2.15
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.56
+1.87%
|
5.46
+41.35%
|
3.86
+45.00%
|
2.66
|
| Current Debt And Capital Lease Obligation |
|
1.17
+10.88%
|
1.06
+20.52%
|
0.88
+20.80%
|
0.73
|
| Current Capital Lease Obligation |
|
1.17
+10.88%
|
1.06
+20.52%
|
0.88
+20.80%
|
0.73
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Total Non Current Liabilities Net Minority Interest |
|
1.54
-40.61%
|
2.59
-31.30%
|
3.77
-11.05%
|
4.24
|
| Long Term Debt And Capital Lease Obligation |
|
1.54
-40.61%
|
2.59
-31.30%
|
3.77
-11.05%
|
4.24
|
| Long Term Capital Lease Obligation |
|
1.54
-40.61%
|
2.59
-31.30%
|
3.77
-11.05%
|
4.24
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Common Stock Equity |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Capital Stock |
|
0.03
+0.00%
|
0.03
+34.78%
|
0.02
+4.55%
|
0.02
|
| Common Stock |
|
0.03
+0.00%
|
0.03
+34.78%
|
0.02
+4.55%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
31.65
+1.34%
|
31.23
+38.67%
|
22.52
+2.75%
|
21.92
|
| Ordinary Shares Number |
|
31.65
+1.34%
|
31.23
+38.67%
|
22.52
+2.75%
|
21.92
|
| Additional Paid In Capital |
|
387.25
+3.74%
|
373.28
+57.06%
|
237.68
+4.90%
|
226.58
|
| Retained Earnings |
|
-274.88
-39.55%
|
-196.98
-69.19%
|
-116.42
-107.77%
|
-56.03
|
| Gains Losses Not Affecting Retained Earnings |
|
0.11
-75.17%
|
0.45
+638.55%
|
-0.08
+12.63%
|
-0.10
|
| Other Equity Adjustments |
|
0.11
-75.17%
|
0.45
+638.55%
|
-0.08
+12.63%
|
-0.10
|
| Total Equity Gross Minority Interest |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Total Capitalization |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Working Capital |
|
104.78
-36.27%
|
164.41
+41.26%
|
116.39
-7.32%
|
125.58
|
| Invested Capital |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Total Debt |
|
2.71
-25.68%
|
3.65
-21.51%
|
4.64
-6.39%
|
4.96
|
| Capital Lease Obligations |
|
2.71
-25.68%
|
3.65
-21.51%
|
4.64
-6.39%
|
4.96
|
| Net Tangible Assets |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Tangible Book Value |
|
112.52
-36.35%
|
176.79
+45.87%
|
121.19
-28.91%
|
170.47
|
| Available For Sale Securities |
|
—
|
5.09
|
—
|
—
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
—
|
| Investmentin Financial Assets |
|
0.00
-100.00%
|
5.09
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-63.66
+3.05%
|
-65.67
-54.00%
|
-42.64
-41.58%
|
-30.12
|
| Cash Flow From Continuing Operating Activities |
|
-63.66
+3.05%
|
-65.67
-54.00%
|
-42.64
-41.58%
|
-30.12
|
| Net Income From Continuing Operations |
|
-77.91
+3.29%
|
-80.56
-33.40%
|
-60.39
-93.76%
|
-31.17
|
| Depreciation Amortization Depletion |
|
1.36
+34.79%
|
1.01
+87.69%
|
0.54
+47.25%
|
0.36
|
| Depreciation |
|
1.36
+34.79%
|
1.01
+87.69%
|
0.54
+47.25%
|
0.36
|
| Depreciation And Amortization |
|
1.36
+34.79%
|
1.01
+87.69%
|
0.54
+47.25%
|
0.36
|
| Other Non Cash Items |
|
1.03
+10.19%
|
0.93
+19.79%
|
0.78
+6.43%
|
0.73
|
| Stock Based Compensation |
|
14.72
+3.02%
|
14.29
+22.98%
|
11.62
+431.72%
|
2.19
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-2.43
-199.51%
|
2.44
-70.04%
|
8.14
+631.20%
|
-1.53
|
| Change In Prepaid Assets |
|
0.19
-19.83%
|
0.24
-88.77%
|
2.11
+159.62%
|
-3.54
|
| Change In Payables And Accrued Expense |
|
-1.82
-140.97%
|
4.43
-34.61%
|
6.78
+153.63%
|
2.67
|
| Change In Accrued Expense |
|
-3.35
-141.80%
|
8.02
+152.79%
|
3.17
+8.70%
|
2.92
|
| Change In Payable |
|
1.54
+142.83%
|
-3.59
-199.36%
|
3.61
+1573.06%
|
-0.24
|
| Change In Account Payable |
|
1.54
+142.83%
|
-3.59
-199.36%
|
3.61
+1573.06%
|
-0.24
|
| Change In Other Current Assets |
|
0.14
+111.62%
|
-1.18
|
0.00
|
—
|
| Change In Other Current Liabilities |
|
-0.94
+11.28%
|
-1.05
-39.92%
|
-0.75
-13.04%
|
-0.67
|
| Investing Cash Flow |
|
66.10
+227.68%
|
-51.77
-202.08%
|
50.72
+135.80%
|
-141.68
|
| Cash Flow From Continuing Investing Activities |
|
66.10
+227.68%
|
-51.77
-202.08%
|
50.72
+135.80%
|
-141.68
|
| Net PPE Purchase And Sale |
|
-1.67
+39.70%
|
-2.77
-114.91%
|
-1.29
+40.54%
|
-2.17
|
| Purchase Of PPE |
|
-1.67
+39.70%
|
-2.77
-114.91%
|
-1.29
+40.54%
|
-2.17
|
| Capital Expenditure |
|
-1.67
+39.70%
|
-2.77
-114.91%
|
-1.29
+40.54%
|
-2.17
|
| Net Investment Purchase And Sale |
|
67.77
+238.30%
|
-49.00
-194.23%
|
52.01
+137.28%
|
-139.51
|
| Purchase Of Investment |
|
-81.73
+59.72%
|
-202.93
-258.98%
|
-56.53
+62.36%
|
-150.18
|
| Sale Of Investment |
|
149.50
-2.87%
|
153.92
+41.82%
|
108.53
+917.37%
|
10.67
|
| Financing Cash Flow |
|
-0.75
-100.62%
|
121.03
+7888.10%
|
-1.55
-101.53%
|
101.71
|
| Cash Flow From Continuing Financing Activities |
|
-0.75
-100.62%
|
121.03
+7888.10%
|
-1.55
-101.53%
|
101.71
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
70.00
|
0.00
-100.00%
|
104.46
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
60.09
+7653.94%
|
0.78
+3129.17%
|
0.02
|
| Net Other Financing Charges |
|
-0.75
+91.72%
|
-9.06
-289.14%
|
-2.33
+16.01%
|
-2.77
|
| Changes In Cash |
|
1.69
-53.00%
|
3.59
-45.00%
|
6.52
+109.31%
|
-70.08
|
| Beginning Cash Position |
|
40.02
+9.85%
|
36.43
+21.81%
|
29.91
-70.09%
|
99.99
|
| End Cash Position |
|
41.70
+4.21%
|
40.02
+9.85%
|
36.43
+21.81%
|
29.91
|
| Free Cash Flow |
|
-65.33
+4.53%
|
-68.44
-55.79%
|
-43.93
-36.07%
|
-32.28
|
| Amortization Of Securities |
|
-0.44
+88.43%
|
-3.78
-13.66%
|
-3.32
-376.07%
|
-0.70
|
| Common Stock Issuance |
|
0.00
-100.00%
|
70.00
|
0.00
-100.00%
|
104.46
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
70.00
|
0.00
-100.00%
|
104.46
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 10-K2026-03-19 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 8-K2026-03-02 View
- 8-K2026-02-27 View
- 42026-02-24 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-02-18 View
- 42026-01-21 View
- 42026-01-16 View
- 42026-01-16 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|